Promising therapeutic prospects for Triple-Negative Breast Cancer

Share

The McPeak-Sirois Group, a breast cancer clinical research consortium is pleased to announce the launch of a new global, randomized Phase 3 clinical trial,  TROPION-Breast04.  This trial is intended for patients with triple-negative breast cancer (TNBC) or hormone-receptor (HR)-low/HER2-negative early stage breast cancer who have not yet received treatment.  The trial will evaluate the safety and efficacy of neoadjuvant datopotamab deruxtecan (or Dato-DXd) in combination with durvalumab, followed by adjuvant durvalumab with or without chemotherapy compared to existing standard treatment for TNBC.  We are proud to report that the first patient worldwide to be enrolled in this pivotal trial is a patient of the Cedars Cancer Centre of the McGill University Health Centre (MUHC).

TNBC has a high recurrence rate and a high potential for metastasis.  It shows resistance to conventional treatments, leading to poor prognosis and survival outcomes. TNBC tends to be more common in women under 40 years of age.  There is a need for novel and more effective treatment approaches, hence the excitement for the TROPION-Breast04 clinical trial which has the potential to improve the lives of eligible patients in this setting. 

The study aims to enroll approximately 1,700 patients with TNBC or HR-low/HER2-negative breast cancer in 19 countries across five continents.  The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo. 

This study is locally led by Dr. Jamil Asselah, a medical oncologist at the MUHC, an investigator in the Cancer Research Program at the Research Institute of the MUHC as well as Chair of the Scientific Committee of the McPeak-Sirois Group.  Dr. Asselah is also a member of the study’s global Steering Committee.  Dr. Asselah states: “Soon, in Quebec, in Canada, and in many other countries, patients diagnosed with triple-negative or HR-low/HER2-newgative breast cancer will have an exceptional opportunity to participate in a Phase 3 study exploring innovative drugs. This study offers, in my opinion, a unique chance to improve the chances of recovery, reduce the risk of relapse and enhance quality of life. I strongly encourage all patients considering neoadjuvant chemotherapy to discuss this opportunity with their oncologist».  

Mrs. Nancie Brunet, a patient who received Dato-DXd with durvalumab as adjuvant therapy in a previous study, shares her treatment experience in this video

In TNBC, cancer cells do not have any of the three usual targets for breast cancer treatments, namely estrogen receptor (ER), progesterone receptor (PR) and HER2 protein, hence the “triple negative” label.  Dato-DXd is an antibody drug conjugate (ADC) designed to target TROP2, a protein that can be expressed on the surface of cancer cells, and to selectively deliver a highly potent payload that damages or eradicates the cancer cells. Durvalumab is an immunotherapy, meaning it works with the immune system to find and attack cancer cells. Both Dato-DXd and durvalumab are given by intravenous infusion.

Patients in the trial will be randomly assigned to two groups. The first group will receive neoadjuvant (preoperative treatment that aims to reduce the size of the tumour) Dato-DXd in combination with durvalumab, followed by adjuvant treatment with durvalumab with or without chemotherapy. The second group will receive neoadjuvant pembrolizumab with chemotherapy, followed by adjuvant treatment with pembrolizumab with or without chemotherapy. The results of each group will be compared.

Those interested in participating in the clinical trial are invited to contact [email protected]

Quotes :

Dr. Dominique Johnson, Executive Director of the McPeak-Sirois Group, says: “We are proud to participate in this important international study and that six of the seven Quebec hospitals participating in this study are members of our organization.  This significant participation by our Group makes it possible to offer access to these innovative and promising treatments to patients from several regions of Quebec.”  Participating hospitals from our Group include McGill University Health Centre, Jewish General Hospital, Centre hospitalier de l’Université de Montréal, Hôpital Maisonneuve-Rosemont, Centre hospitalier universitaire de Sherbrooke and Hôtel-Dieu de Lévis.

Kimberly Carson, CEO of Breast Cancer Canada, is inspired by the contributions from 17 hospitals across the country, along with the opportunity for Canadian patients to take part: “With more research, we know we can end breast cancer. We urge breast cancer patients who are eligible to consider participating in this pivotal Canadian study. Together we can make progress and change breast cancer outcomes.

For Cédric Baudinet, Director, Investments and health promotion at the Quebec Breast Cancer Foundation: “The launch of the TROPION-Breast04 trial is a fantastic opportunity for people affected by TNBC to benefit from an additional therapeutic option, in a context where they are limited for this type of cancer. It is of course a note of hope for people affected by breast cancer but also great news for access to the best therapies in Quebec thanks to clinical research”.

About TROPION-Breast04
TROPION-Breast04 is a global, randomised, open-label, double-arm, Phase 3 trial evaluating the efficacy and safety of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in patients with previously untreated Stage II-III TNBC or HR-low/HER2-negative breast cancer.  

The primary endpoints of TROPION-Breast04 are pathological complete response and event-free survival. A key secondary endpoint is overall survival (OS) and additional secondary endpoints include distant disease-free survival, participant-reported outcomes, pharmacokinetics, immunogenicity, and safety and tolerability.

TROPION-Breast04 will enroll approximately 1,700 patients with previously untreated TNBC or HR-low/HER2-negative breast cancer at study sites in Asia, Europe, North and South America, and Australia.  Daiichi Sankyo and AstraZeneca are leading an extensive clinical development program for datopotamab deruxtecan for the treatment of TNBC, including TROPION-Breast04. 

About the McPeak-Sirois Group
The McPeak-Sirois Group is a charitable organization whose mission is to fight breast cancer more effectively by increasing patients’ access and participation to clinical trials. The Group’s scientific committee is made up of internationally renowned scientists who oversee the selection of clinical studies offered to the consortium’s member hospitals. Co-founded in 2015 by Susan McPeak, a breast cancer survivor, and Charles Sirois, a well-known entrepreneur, the McPeak-Sirois Group is committed to promoting research that cares by bringing it closer to breast cancer patients throughout Quebec.

About Breast Cancer Canada
Breast Cancer Canada is a national charity dedicated to saving lives through breast cancer research. With a focus on precision oncology (personalized care), it is the only national breast cancer organization in Canada that has a clear mandate to raise money for research. The organization receives no government funding, meaning all research is funded through the generosity of donors. 

About the Quebec Breast Cancer Foundation
For more than 29 years, the Quebec Breast Cancer Foundation has been putting people with breast cancer and their loved ones at the heart of its mission through research and innovation, support and awareness. The QBCF has raised more than $64 million in Quebec, which has been distributed in Quebec for cutting-edge research and to defend the interests of people with breast cancer and their loved ones. Families, researchers, volunteers, and donors all share the same hope: a future without breast cancer

Media Contact

Marine Baillie, Communications Advisor
McPeak-Sirois Group
[email protected]

Media Contact – for interviews with Dr. Jamil Asselah

Fabienne Landry
Communications coordinator, Research
McGill University Health Centre
[email protected]

Donate Today

When you support Breast Cancer Canada, you are helping to improve and save lives through better treatments and early detection of breast cancer.

1 in 8 Canadian women
will be diagnosed with breast cancer.

Get Involved

The more money we raise, the sooner we can end breast cancer. Join us on our mission to end breast cancer.

I am a

Individual Donor

When you support Breast Cancer Canada, you are helping to improve and save lives through better treatments and early detection of breast cancer.

Learn more about

Gifting securities

Donating securities is becoming more popular, and supports Breast Cancer Canada just like cash donations. Gifts of publicly traded securities (stocks, bonds, mutual funds) are an easy, tax-effective way to make a contribution towards life-saving research that helps with early detection, better treatments, and ultimately  Securities can be of any size and given immediately, or you can bequeath them to Breast Cancer Canada in your will. Just like a cash donation, you’ll get a donation tax credit for your gift of securities.

Today, most securities are held electronically and are easily transferred from your brokerage account to our BCC brokerage account. Your Financial Advisor can make all the arrangements.

For more information, contact Natalina Hamilton: [email protected]

Send e-cards in memory or honour

Bravery is beautiful. That’s why we encourage you to make a donation in honour of a loved one’s own experience with breast cancer. With your donation, we’ll send a email to acknowledge the dedication to the individual or family.

Make a donation with  eCard by dedicating your donation:

Let’s get started

Corporate matching

Multiply the impact of your donation

Fact: thousands of companies will match donations made by employees.

It’s true, and it’s very generous. Want to know if your company will match your donation to BCC? Use the search tool below. It also has access to all the forms, guidelines, and instructions you need to submit a company-matchable gift donation today.

Search Tool

Monthly Giving

Support life-saving breast cancer research every month of the year.

 

When you make a monthly contribution to Breast Cancer Canada, you provide stable funding for year-round campaigning and allow us to continue to support research projects across Canada.

 

To join, simply pre-authorize a monthly deduction from your credit card.

  1. Online:  Donate Now
  2. By Phone: Sign up as a monthly donor by calling Toll Free: 1-800-567-8767
  3. By Mail


Breast Cancer Canada, National Office
415 Exmouth Street Unit # 101
Sarnia, ON N7T 8A4

You will need to provide us the credit card type, number and expiry date, and the amount you would like to give each month.

I am a

Legacy Donor

Over the last 30 years, many generous donors have left a legacy to Breast Cancer Canada in efforts to advance breast cancer research.

No matter what the form of your gift, you will be remembered by your legacy which will live on through each of the lives you touch with your gift.

Learn more about

Legacy donor

Leave a legacy. Plan for a future gift.

  • Leave a gift in your will
  • Donating a life insurance policy
  • Donate a TFSA, RRSP, or RRIF

Support Breast Cancer Canada with a future gift to create a better future for breast cancer patients. Your gift helps to save lives through early detection and improve outcomes with better treatments.

or more information, please contact Natalina Hamilton: [email protected]


LEAVE A GIFT IN YOUR WILL

This is often called a bequest. It’s the simplest way to make a legacy gift. A gift in your will has no effect on your current income and your estate receives a charitable donation tax receipt. Here’s a sample of simple bequest wording : “To pay the sum of $_________ OR _______% of the residue of my estate to Breast Cancer Canada.”


DONATING A LIFE INSURANCE POLICY

Life insurance is a way to provide financial security for your family. If the needs of your family are already taken care of, a life insurance policy is a smart way to donate to charity including tax savings for your estate. Speak to your financial advisors for your personalized advice and learn how a gift of life insurance can work for you. Here’s the top-line on ways of leaving gifts of life insurance:


Bequeath your policy to Breast Cancer Canada for the future:

  • Name Breast Cancer Canada as the beneficiary of your policy. BCC will receive your insurance proceeds tax-free. Your estate will receive a donation receipt.


Transfer ownership of a paid-up policy to Breast Cancer Canada now:

  • Want to gift us your existing, paid-up policy right now? Make Breast Cancer Canada the beneficiary and owner of your policy. You will receive a donation receipt for the fair market value of the policy. BCC may redeem the policy now, or hold it and receive the face value in the future – however your gift can be put to best use.


Transfer ownership of a policy on which premiums are still owing to BCC now:

  • Premiums still owing? You can still opt to transfer your policy ownership to BCC. You’ll receive a donation receipt for the policy’s fair market value. Want to make it an ongoing gift? Transfer the ownership to BCC, and still continue to pay the premiums owing. You’ll receive donation receipts for those payments too.


DONATE A TFSA, RRSP, RRIF

Register a significant difference in the lives of those affected by breast cancer. Donate the proceeds of a registered account: Tax-free savings account (TFSA); Registered retirement savings plan (RRSP); Registered retirement income fund (RRIF). It’s a smart way to make a major contribution. Without reducing your current assets. Without subjecting the funds to probate fees. While reducing taxes on your estate through a donation receipt.

Making a gift like this is easy. Designate Breast Cancer Canada as the beneficiary of your registered account.  You benefit from the full use of your account(s) during your lifetime. We receive any remaining funds after your passing.

For more information, contact Natalina Hamilton: [email protected]

I am a

Corporate Donor

Support life-saving breast cancer research. A corporate donation is a simple and efficient way to demonstrate your corporate support.

To make a one-time or reoccurring corporate donation online, please click here.

Learn more about

How to Sponsor

Thinking about becoming a corporate partner of Breast Cancer Canada? Amazing. work with all types of organizations. We’ll help you deliver results which are measurable. National or local.

A partnership with Breast Cancer Canada is a win-win. It improves employee engagement, boosts morale, fosters a tighter culture. It raises your organization’s profile and demonstrates your support for breast cancer research. To customers. To employees. To suppliers. Most of all – it makes a positive impact for those affected directly by breast cancer.

We’ll raise money for life-saving breast cancer research, together.

Let’s talk about building your program!

Contact Dawn Hamilton today to get started.
Email: [email protected]
Phone: 1-800-567-8767 

To make an online corporate donation, please click here.

How to

Support an Event

Make a contribution to a fundraiser being held in support of Breast Cancer Canada. You can search for the organization or person you wish to support; or click on the event name to make a general donation to the Raise More initiative of your choice.

How to

Sponsor

Thinking about becoming a corporate partner of Breast Cancer Canada? Amazing. We work with all types of organizations. We’ll help you deliver results which are measurable. National or local.

A partnership with Breast Cancer Canada is a win-win. It improves employee engagement, boosts morale, fosters a tighter culture. It raises your organization’s profile and demonstrates your support for breast cancer research. To customers. To employees. To suppliers. Most of all – it makes a positive impact for those affected directly by breast cancer.

We’ll raise money for life-saving breast cancer research, together.

Let’s talk about building your program!

Contact Charlene Politano today to get started.
Email: [email protected]
Phone: 1-800-567-8767 or 416-352-8567

To make an online corporate donation, please click here.

If you would like to explore other ways to give, we invite you to learn more.

How to

Fundraise

Join the Raise More Challenge

The more money we raise, the sooner we can end breast cancer. The more time researchers have in the lab. The more technology they can use. The more support we can get. Advancements in early detection and personalized treatment are in reach, and with your help to raise funds, we can find a cure sooner.

There are many ways to fundraise – whether you want to create a competition or tournament, fundraise with your team, challenge your colleagues, host a pink party, have a bake sale or cook-off, the idea is to raise more for breast cancer research.

Breast Cancer Canada will empower you with all the tools you need for a successful fundraiser, and if you need more information, contact Dawn Hamilton at: [email protected]  

How to

Volunteer

Volunteers are Breast Cancer Canada’s most important resource, and the backbone of our organization. From helping build our PROgress research to helping breast cancer patients, to supporting events, special fundraising projects and administrative tasks, our volunteers are dedicated to making a positive, life-changing impact.

We ensure our volunteers have the best possible experience and apply the Canadian Code for Volunteer Involvement.

You can help us end breast cancer by:

  • Volunteering with one of our fundraising campaigns. Or a BCC signature event
  • Helping with local community events where you live
  • Joining our PROgress research at a local hub
  • Assisting us with virtual office tasks

Learn more about our volunteer driven Regional Hubs.

Regional Hubs are an integral part of Breast Canada Canada. We connect communities and those committed to our mission to make the goal local. Together, we can save lives through advancing breast cancer research, coast to coast.

Connect to learn more about what is happening in your area: [email protected]